Main complications associated with the administration of intraperitoneal and intravenous chemotherapy in ovarian cancer patients

Authors

  • Mercedes Palmés Ferrera Hospital Clínic de Barcelona
  • Cassandra Ixena Andersson Vila Hospital Clinic de Barcelona
  • Maria del Carmen Barrera Reyes Hospital Clinic de Barcelona
  • Maria del Carmen García Gigán Hospital Clinic de Barcelona
  • Maria Alba Graells Piqué Hospital Clinic de Barcelona
  • Esther Gómez Rodríguez Hospital Clinic de Barcelona
DOI: https://doi.org/10.6018/eglobal.16.3.260351
Keywords: Intraperitoneal chemotherapy, nursing care, ovarian cancer, adverse effects, complications, toxicity.

Supporting Agencies

  • Aleix Prat
  • ICMHO
  • CEIC Hospital Clinic de Barcelona.

Abstract

Background: Ovarian cancer displays the highest death rates amongst all gynaecologic cancers. Most cases are diagnosed at an advanced stage of the disease and the treatment of choice is generally the combination therapy of intraperitoneal (IP) and intravenous (IV) chemotherapy. While this approach has been shown to prolong survival, multiple associated toxicities have been reported.
Objective: To identify the side effects and complications resulting from IP+IV chemotherapy treatment in stage III and stage IV ovarian cancer patients during the 2007-2015 period.
Methods:  A descriptive, longitudinal and retrospective study was performed. A group of 17 women diagnosed with stage III and stage IV ovarian cancer were treated with IP+IV chemotherapy in Hospital Clínic de Barcelona during the period 2007-2015.
Results: Of the 17 patients who were treated with IP+IV chemotherapy, only 5 (29,41%) completed the 6 cycles of treatment. Notably, 12 (70,58%) patients discontinued the treatment due to a series of complications, which were frequently associated with IP reservoir and psychological disorders. The most commonly reported side effects were asthenia, neurotoxicity and abdominal pain.
Conclusions:  The majority of patients discontinued their prescribed therapy due to complications associated with IP reservoir and psychological disorders. We believe that the nurse plays a key role, not only in managing the technical aspects of the therapy but also in providing patients with emotional support throughout their journey.

Downloads

Download data is not yet available.

References

Lesnock J, Richard S, Zorn K, Krivak T, Beriwal S, Sukumvanich P et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecologic Oncology. 2010;116(3):345-350.

: Sociedad Española de oncología médica. Las cifras del cáncer 2014 [Internet]. 2014 [cited 25 January 2016]. Available from: http://www.seom.org/seomcms/images/stories/recursos/Las_cifras_del_cancer_2014.pdf

: Sociedad española de oncología médica. Cáncer de ovario [Internet]. 2015 [cited 25 January 2016]. Available from: http://www.seom.org/en/informacion-sobre-el-cancer/info-tipos-cancer/ginecologico/ovario?showall=1

Cristea M, Han E, Salmon L, Morgan R. Review: Practical considerations in ovarian cancer chemotherapy. Therapeutic Advances in Medical Oncology. 2010;2(3):175-187.

Drake, B. Intraperitoneal chemotherapy: a reemerging approach in the treatment of ovarian cancer.Journal of infusion nursing. 2009 Nov-Dec;32(6):314-22

Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer research. 2009 Jul;29(7):2803-8.

Gray H, Shah C, Swensen R, Tamimi H, Goff B. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecologic Oncology. 2010;116(3):340-344.

Trimble E, Thompson S, Christian M, Minasian L. Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer. The Oncologist. 2008;13(4):403-409.

Armstrong DK, Fujiwara K, Jelovac D. Intraperitoneal treatment in ovarian cancer: the gynecologic oncology group perspective in 2012. Am Soc Clin Oncol Educ Book. 2012:345-8.

Wenzel L, Huang H, Armstrong D, Walker J, Cella D. Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007;25(4):437-443.

Bowles E, Wernli K, Gray H, Bogart A, Delate T, O’Keeffe-Rosetti M et al. Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation. Front Oncol. 2014;4.

Hess LM, Alberts DS. The role of intraperitoneal therapy in advanced ovarian cancer. Oncology (Williston Park). 2007 Feb;21(2):227-32.

Landrum L, Gold M, Moore K, Myers T, McMeekin D, Walker J. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: A review of complications and completion rates. Gynecologic Oncology. 2008;108(2):342-347.

Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere S, Tambaro R et al. Ovarian cancer standard of care: are there real alternatives?. Chin J Cancer. 2015;34(1):17-27.

Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield P, Grant P et al. Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology. 2013;24(4):359.

Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007 Feb 15;109(4):692-702.

Robinson W, Coberly C, Beyer J, Lewis A, Ballard C. Office-Based Intraperitoneal Chemotherapy for Ovarian Cancer. Journal of Oncology Practice. 2008;4(5):225-228.

Jim H, Barata A, Wenham R, Jacobsen P. Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study. International Journal of Psychological Research. 2013; 6(1): 8-14.

Jaka R, Somashekhar S, Zaveri S, Ahmed Z, Ashwin K. Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer – Single Center Experience. Indian J Surg Oncol. 2012;3(3):262-266.

Armstrong DK, Fujiwara K, Jelovac D. Intraperitoneal treatment in ovarian cancer: the gynecologic oncology group perspective in 2012. Am Soc Clin Oncol Educ Book. 2012:345-8.

Anderson N, Hacker E. Fatigue in Women Receiving Intraperitoneal Chemotherapy for Ovarian Cancer A Review of Contributing Factors. Clinical Journal of Oncology Nursing. 2008;12(3):445-454.

Chua T, Chan, Rao, Morris D. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Management and Research. 2012;:413.

Published
28-06-2017
How to Cite
[1]
Palmés Ferrera, M. et al. 2017. Main complications associated with the administration of intraperitoneal and intravenous chemotherapy in ovarian cancer patients. Global Nursing. 16, 3 (Jun. 2017), 175–192. DOI:https://doi.org/10.6018/eglobal.16.3.260351.
Issue
Section
ORIGINAL RESEARCH